Search

Your search keyword '"Caserta, Enrico"' showing total 16 results
Start Over Author "Caserta, Enrico" Journal blood
16 results on '"Caserta, Enrico"'

1. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Author

Murtadha, Mariam, Park, Miso, Zhu, Yinghui, Caserta, Enrico, Napolitano, Ottavio, Tandoh, Theophilus, Moloudizargari, Milad, Pozhitkov, Alex, Singer, Mahmoud, Dona, Ada Alice, Vahed, Hawa, Gonzalez, Asaul, Ly, Kevin, Ouyang, Ching, Sanchez, James F., Nigam, Lokesh, Duplan, Amanda, Chowdhury, Arnab, Ghoda, Lucy, Li, Ling, Zhang, Bin, Krishnan, Amrita, Marcucci, Guido, Williams, John C., and Pichiorri, Flavia

Published
2024
Full Text
View/download PDF

2. CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Author

Zhu, Yinghui, primary, Park, Miso, additional, Murtadha, Mariam, additional, Caserta, Enrico, additional, Nguyen, Le Xuan Truong, additional, Singer, Mahmoud, additional, Estepa, Marc Denisse, additional, Nigam, Lokesh, additional, Dona', Ada Alice, additional, Sanchez, James F, additional, Tandoh, Theophilus, additional, Li, Man, additional, Zhang, Bin, additional, Kuo, Ya-Huei, additional, Marcucci, Guido, additional, Williams, John C, additional, and Pichiorri, Flavia, additional

Published
2022
Full Text
View/download PDF

5. First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Author

Krishnan, Amrita Y., primary, Adhikarla, Vikram, additional, Chaudhry, Ammar, additional, Palmer, Joycelynne, additional, Poku, Erasmus K, additional, Biglang-awa, Van Eric, additional, Bowles, Nicole, additional, Nathwani, Nitya, additional, Rosenzweig, Michael, additional, Sahebi, Firoozeh, additional, Karanes, Chatchada, additional, Simpson, Jennifer, additional, Sanchez, James F, additional, Yamauchi, David, additional, Parayno, Maria, additional, Chowdhury, Arnab, additional, Caserta, Enrico, additional, Wu, Anna, additional, Forman, Stephen J, additional, Colcher, David, additional, Yazaki, Paul, additional, Shively, John E., additional, and Pichiorri, Flavia, additional

Published
2019
Full Text
View/download PDF

6. Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Author

Dona', Ada, primary, Viola, Domenico, additional, Caserta, Enrico, additional, Besi, Francesca, additional, Sanchez, James F, additional, Marcucci, Guido, additional, Keats, Jonathan J, additional, Krishnan, Amrita Y., additional, Coffey, Matt, additional, Sborov, Douglas W., additional, Nuovo, Gerard, additional, Hofmeister, Craig C, additional, and Pichiorri, Flavia, additional

Published
2019
Full Text
View/download PDF

7. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Author

Caserta, Enrico, Chea, Junie, Minnix, Megan, Poku, Erasmus K., Viola, Domenico, Vonderfecht, Steven, Yazaki, Paul, Crow, Desiree, Khalife, Jihane, Sanchez, James F., Palmer, Joycelynne M., Hui, Susanta, Carlesso, Nadia, Keats, Jonathan, Kim, Young, Buettner, Ralf, Marcucci, Guido, Rosen, Steven, Shively, John, Colcher, David, Krishnan, Amrita, and Pichiorri, Flavia

Published
2018
Full Text
View/download PDF

8. CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Author

Gunes, Emine Gulsen, primary, Lewinsky, Hadas, additional, Viola, Domenico, additional, Caserta, Enrico, additional, Rosenzweig, Michael, additional, Htut, Myo, additional, Sanchez, James F, additional, Buettner, Ralf, additional, Marcucci, Guido, additional, Keats, Jonathan J, additional, Krishnan, Amrita, additional, Rosen, Steven T, additional, Shachar, Idit, additional, and Pichiorri, Flavia, additional

Published
2018
Full Text
View/download PDF

11. Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Author

Moloudizargari, Milad, Dona, Ada Alice, Park, Miso, Tandoh, Theophilus, Murtadha, Mariam, Caserta, Enrico, Pozhitkov, Alexander, Zhu, Yinghui, Napolitano, Ottavio, Sanchez, James, Nigam, Lokesh, Duplan, Amanda, Chowdhury, Arnab, Ghoda, Lucy Y., Keats, Jonathan, Goldsmith, Scott R., Rosenzweig, Michael, Krishnan, Amrita, Williams, John C., and Pichiorri, Flavia

Abstract

The use of immune checkpoint inhibitors has markedly improved the survival outcomes of many patients with solid tumors. However, in multiple myeloma (MM), the use of such inhibitors has failed to achieve survival benefit. We previously showed that oncolytic herpes simplex virus 1 (oHSV-1) can effectively infect MM cells and induce apoptosis through the receptors for oHSV-1, NECTIN-1 and HVEM (herpes virus entry mediator). HVEM, a member of the TNF receptor superfamily (TNFRSF14), is an immune checkpoint present on T cells, B cells, NK cells and macrophages. Depending on HVEM's interaction with its major inhibitory ligand, B- and T-lymphocyte attenuator (BTLA) or its major activating ligand, tumor necrosis factor superfamily member 14 (TNFSF14, LIGHT), it is pivotal in downmodulating or stimulating the immune cells. Accordingly, targeting HVEM to block its interaction with BTLA is an area of therapeutic interest.

Published
2023
Full Text
View/download PDF

12. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Author

Radomska, Hanna, primary, Canella, Alessandro, additional, Jessica, Consiglio, additional, Rocci, Alberto, additional, Luciano, Cascione, additional, Cordero, Hector, additional, Joseph, Liu, additional, Caserta, Enrico, additional, Ramasamy, Santhanam, additional, Efebera, Yvonne A., additional, Volinia, Stefano, additional, Hofmeister, Craig C, additional, and Pichiorri, Flavia, additional

Published
2015
Full Text
View/download PDF

13. Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia

Author

Mishra, Anjali, primary, Liu, Shujun, additional, Sams, Gregory H, additional, Curphey, Douglas P, additional, Santhanam, Ramasamy, additional, Rush, Laura J, additional, Schaefer, Deanna, additional, Falkenberg, Lauren G, additional, Sullivan, Laura, additional, Jaroncyk, Laura, additional, Zou, Xunchang, additional, Fisk, Harold, additional, Labanowska, Jadwiga, additional, Caserta, Enrico, additional, Wu, Lai-Chu, additional, Becker, Heiko, additional, Schwind, Sebastian, additional, Chandler, Jason C., additional, Wu, Yue-Zhong, additional, Heerema, Nyla A., additional, Porcu, Pierluigi, additional, Garzon, Ramiro, additional, Marcucci, Guido, additional, and Caligiuri, Michael A., additional

Published
2010
Full Text
View/download PDF

14. MiR- 16Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages

Author

Khalife, Jihane, Viola, Domenico, Ghose, Jayeeta, Weingart, Robert, Sanchez, James F, Hofmeister, Craig C, Krishnan, Amrita, Marcucci, Guido, Carlesso, Nadia, Caserta, Enrico, and Pichiorri, Flavia

Abstract

Introduction:Multiple myeloma plasma cells (MM-PCs) home to and dynamically interact with the bone marrow (BM) microenvironment (BM-ME). Of the different factors secreted by the BM-ME, NF-κB-induced cytokines including IL-6 play a central role in MM-PC survival and resistance to treatments. Previously published data have shown that in the BM of MM patients the presence of CD163+ tumor associated macrophages (TAM) correlates with IL-6 production. The canonical NF-κB pathway is induced by most physiological stimuli to produce low levels of inflammatory cytokines, through the activation of the IκB kinase complex (IKKβ, IKKα, and IKKγ). This pathway seems constitutively activated in TAM, where instead the activation of the non-canonical pathway seems to play a critical role in the anti-cancer phenotype of BM macrophages (BM-Mϕ).

Published
2017
Full Text
View/download PDF

16. Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Author

Caserta, Enrico, Chea, Junie, Minnix, Megan, Viola, Domenico, Vonderfecht, Steven, Keats, Jonathan J, Sanchez, James F, Colcher, David, Shively, John E., Krishnan, Amrita, and Pichiorri, Flavia

Abstract

Introduction: Minimal residual disease (MRD) is known to be an independent predictor of progression free survival (PFS) in multiple myeloma (MM). Methods of MRD detection include flow cytometry, PCR based sequencing, and imaging. However, irrespective of the sensitivity of MRD detection, techniques based on bone marrow biopsies cannot account for a “patchy,” non-homogenous bone marrow infiltration. Positron emission tomography (PET) coupled with computed tomography (CT) using 18fluoro-deoxyglucose as the radiotracer (18FDG-PET) is a commonly used imaging method that is much more sensitive than traditional radiographs, but it has several limitations; for one, lesions with a low metabolic rate may result in false negatives. Also, diffuse tracer uptake by normal marrow can obscure focal MM lesions. Daratumumab (Dara), a human anti-CD38 IgG1(ĸ subclass) antibody against the highly expressed plasma cell receptor CD38, has been recently approved by the FDA for the treatment of MM. Based on the idea that Dara can selectively target MM cells irrespective of their metabolism, our group labeled Dara with the positron-emitting isotope copper-64 (64Cu-DOTA-Dara) in order to generate a novel imaging agent that can detect MM cells with high specificity. Our group already safely used 64Cu-labeled trastuzumab to detect HER2-positive tissue in breast cancer patients (Mortimer JE et. al. 2014), and here we provide the first pre-clinical evidence that 64Cu-labeled antibodies can be considered powerful imaging tools for MM detection.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results